Boundless Bio (BOLD) Depreciation & Amortization (CF) (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Depreciation & Amortization (CF) of $284000.0 for Q1 2026, down 10.41% year-over-year from $317000.0 in Q1 2025, and down 7.49% quarter-over-quarter from $307000.0 in Q4 2025.
Boundless Bio (BOLD) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $284000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 10.41% year-over-year to $284000.0; the TTM figure through Mar 2026 stood at $1.2 million (up 3.66% YoY), while the FY2025 annual figure was $1.3 million, up 15.19% from the prior year.
- Depreciation & Amortization (CF) declined to $284000.0 in Q1 2026 per BOLD's latest filing, from $307000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $317000.0 in Q1 2025 and bottomed at $200000.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $270230.8 across 4 years, with a median of $284000.0 in 2026.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 50.0% — and 2026, when it fell 10.41%.
- Boundless Bio's Depreciation & Amortization (CF) stood at $247000.0 in 2023, then increased by 19.84% to $296000.0 in 2024, then grew by 3.72% to $307000.0 in 2025, then dropped by 7.49% to $284000.0 in 2026.
- Business Quant data shows BOLD's Depreciation & Amortization (CF) at $284000.0 in Q1 2026, $307000.0 in Q4 2025, and $310000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Mn |
| Jun 30, 2026 | 1.26 Mn |
| Mar 31, 2026 | 284,000.00 |
| Mar 31, 2026 | 284,000.00 |
| Dec 31, 2025 | 307,000.00 |
| Dec 31, 2025 | 307,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Sep 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Dec 31, 2024 | 296,000.00 |
| Dec 31, 2024 | 296,000.00 |
| Sep 30, 2024 | 262,000.00 |
| Sep 30, 2024 | 262,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 263,000.00 |
| Mar 31, 2024 | 263,000.00 |